Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Lists
Only you see this
Abstract
Coronavirus disease 2019 (COVID-19) vaccines reduce severe disease and mortality and may lessen transmission, measured by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL). Evaluating vaccine associations in VL at COVID-19 diagnosis in 4 phase 3 randomized, placebo-controlled vaccine trials, July 2020 to July 2021, VL reductions were 2.78 log10 copies/mL (95% confidence interval [CI], 1.38-4.18; n = 60 placebo, 11 vaccine) and 2.12 log10 copies/mL (95% CI, 1.44-2.80; n = 594 placebo, 36 vaccine) for NVX-CoV2373 and mRNA-1273, respectively. Associations were not significant for AZD1222 (0.59 log10 copies/mL; 95% CI, -.19 to 1.36; n = 90 placebo, 78 vaccine) or Ad26.COV2.S (0.23 log10 copies/mL; 95% CI, -.01 to .47; n = 916 placebo, 424 vaccine). Thus, vaccines potentially decreased transmission when ancestral SARS-CoV-2 predominated. Clinical Trials Registration. NCT04470427, NCT04505722, NCT04516746, NCT04611802.
BibTeX
@article{janes2024association,
author = {Holly Janes and Leigh H. Fisher and Jia Jin Kee and Lalitha Parameswaran and Paul A. Goepfert and Ann R. Falsey and James P. Ludwig and Craig A. Magaret and Peter B. Gilbert and James G. Kublin and Nadine Rouphael and Magdalena E. Sobieszczyk and Hana M. El Sahly and Lindsey R. Baden and Beatriz Grinsztejn and Stephen R. Walsh and Glenda Gray and Karen L. Kotloff and Cynthia L. Gay and Alexander L. Greninger and Milagritos D. Tapia and E. Adrianne Hammershaimb and Frances Priddy and Justin A Green and Frank Struyf and Lisa M. Dunkle and Kathleen M. Neuzil and Lawrence Corey and Yunda Huang},
title = {{Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials}},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae400},
}Loading related content...